Glucose Control in the ICU Using Continuous Glucose Monitoring (REGIMEN)
Critical Illness
About this trial
This is an interventional treatment trial for Critical Illness focused on measuring medical ICU patients, APACHE-II score ≥20
Eligibility Criteria
Inclusion Criteria:
- Patients admitted to a medical intensive care unit
- age: ≥ 18 y , < 75 y
- APACHE II (Acute Physiology and Chronic Health Evaluation II) score ≥ 20
- expected length of stay in ICU > 3 days
Exclusion Criteria:
- pregnancy
- patient with a DNR (do not reanimate) code
- surgical patient
- no informed consent
Sites / Locations
- Middelheim General Hospital
- Antwerp University Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
real-time continuous glucose monitoring
blinded continuous glucose monitoring
real-time continuous glucose monitoring: Use will be made of the online real-time (RT) monitoring facility of the GlucoDay® (a continuous glucose monitoring (CGM)system). This will allow immediate adaptation of the insulin dose in order to maintain values within an optimal range. The same IV insulin infusion protocol will be used in the experimental and the active comparator group (adapted Yale protocol). When glycaemic changes of >25 mg/dl per 30 minutes are observed from the RT-CGM - GlucoDay data, this will be checked by measuring arterial blood glucose and the insulin infusion rate will be adapted according to the adapted Yale protocol.
In the active comparator group the same continuous glucose monitoring device (GlucoDay) will be used in a blinded fashion. Glucose data will be analysed retrospectively. IV insulin infusion will be adapted according to arterial blood glucose values, using the adapted Yale protocol.